The present invention relates to novel triazolo-pyridines of the formula I
1
wherein R
1
is fluoro;
s is an integer from two to three;
R
2
is (C
3
-C
6
)cycloalkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (C
1
-C
4
)alkyl, hydroxy, (C
1
-C
6
)alkoxy and (C
1
-C
6
)alkyl-(C═O)—O—;
or R
2
is (C
1
-C
6
)alkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (C
1
-C
6
)alkyl, hydroxy, (C
1
-C
6
)alkoxy and (C
1
-C
6
)alkyl-(C═O)—O—;
with the proviso that said compound of formula I cannot be
6-[4-(2,4-Difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine; or
6-[4-(3,4-Difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine;
to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
本发明涉及式I1的新型三唑啉-
吡啶化合物,其中R1为
氟;s为2至3的整数;R2为(C3-C6)
环烷基,可选地被一或两个基团独立地选自卤素、(C1-C4)烷基、羟基、(C1-C6)烷
氧基和(C1-C6)烷基-(C═O)-O-;或者R2为(C1-C6)烷基,可选地被一或两个基团独立地选自卤素、(C1-C6)烷基、羟基、(C1-C6)烷
氧基和(C1-C6)烷基-(C═O)-O-;但式I化合物不能是6-[4-(
2,4-二
氟苯基)-
噁唑-5-基]-3-
异丙基-[1,
2,4]三唑啉[4,3-a]
吡啶;或6-[4-(3,4-二
氟苯基)-
噁唑-5-基]-3-
异丙基-[1,
2,4]三唑啉[4,3-a]
吡啶;本发明化合物是
MAP激酶的有效
抑制剂,优选为p38激酶。它们可用于治疗炎症、骨关节炎、类风湿性关节炎、癌症、脑卒中或心脏病的再灌注或缺血、自身免疫性疾病和其他疾病。本发明还涉及其制备的
中间体、含有它们的制药组合物和它们的药用用途。